Equities research analysts at Evercore ISI started coverage on shares of Cabaletta Bio (NASDAQ:CABA) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $25.00 price target on the stock. Evercore ISI’s price objective would suggest a potential upside of 71.00% from the stock’s current price.
Separately, Cowen initiated coverage on Cabaletta Bio in a research report on Tuesday. They issued an “outperform” rating on the stock.
NASDAQ CABA traded down $1.85 during trading hours on Tuesday, reaching $14.62. The stock had a trading volume of 2,975 shares, compared to its average volume of 130,206. Cabaletta Bio has a 52-week low of $8.58 and a 52-week high of $18.28.
About Cabaletta Bio
Cabaletta Bio, Inc operates as a clinical-stage biotechnology company that focuses on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company's proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies or pathogenic B cells.
See Also: Dividend Aristocrat Index
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.